

WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

(51) International Patent Classification <sup>6</sup> : C12N 13/00, 15/09		A1	(11) International Publication Number: WO 98/12310
			(43) International Publication Date: 26 March 1998 (26.03.98)
(21) International Application Number: PCT/US97/16721 (22) International Filing Date: 19 September 1997 (19.09.97) (30) Priority Data: 08/718,658                      23 September 1996 (23.09.96)      US (71) Applicant: DUKE UNIVERSITY [US/US]; Erwin Road, Durham, NC 27706 (US). (71)(72) Applicant and Inventor: MEYER, Tobias [CH/US]; 2628 McDowell Road, Durham, NC 27705 (US). (74) Agents: SIBLEY, Kenneth, D. et al.; Myers Bigel Sibley & Sajovec, P.O. Box 37428, Raleigh, NC 27627 (US).			(81) Designated States: AU, CA, JP, European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).  Published <i>With international search report.</i>

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon	KR	Republic of Korea	PL	Poland		
CN	China	KZ	Kazakhstan	PT	Portugal		
CU	Cuba	LC	Saint Lucia	RO	Romania		
CZ	Czech Republic	LI	Liechtenstein	RU	Russian Federation		
DE	Germany	LK	Sri Lanka	SD	Sudan		
DK	Denmark	LR	Liberia	SE	Sweden		
EE	Estonia			SG	Singapore		

## METHOD OF TRANSFECTING CELLS BY ELECTROPORATION AND APPARATUS FOR SAME

5           This invention was made with Government support under grants GM-48113 and GM-51457 from the National Institutes of Health. The Government has certain rights to this invention.

### Field of the Invention

10           This invention relates to a method of transfecting cells with exogenous compounds by electroporation.

### Background of the Invention

15           Single cell assays to measure signal transduction and other cellular processes are useful for the identification of drug targets, as well as for drug screening. The number of known signaling molecules involved in particular cell functions and disease states is rapidly increasing. At the same time, combinatorial chemistry has dramatically expanded the number of substances that must be tested for their effect on  
20           specific signaling molecules and transduction pathways. Commonly used in vitro measurements of drug-target

binding interactions and other screening methods are often inadequate to assess the effectiveness of drugs within the cellular context, and therefore, the ability to assay intact cells for particular cell functions would be a powerful way to investigate all signaling steps that lead to the monitored event. Currently, the main limitations for this strategy are: (i) the lack of an efficient method to rapidly introduce membrane impermeant molecules into adherent cells using cost efficient amounts of samples and (ii) the limited number of available single cell assays to test for particular cell functions.

### Summary of the Invention

A first aspect of the present invention is an electroporation apparatus for introducing exogenous material into cells. The apparatus comprises a base member configured for holding a cell support, the cell support having a top surface portion, the top surface portion configured for carrying adherent cells; an electrode carrier operably associated with the base member, the electrode carrier having a bottom surface portion; a first electrode connected to the electrode carrier; and a second electrode connected to the electrode carrier. The electrode carrier has a channel formed therein, with the channel positioned between the first electrode and the second electrode, so that the exogenous material may be introduced through the channel and into contact with the cells.

A second aspect of the present invention is a method for transfecting cells with an exogenous compound. The method comprises providing a cell support, with said cell support having a top surface portion with the cells adhered thereto, and with the cells being in contact with (i.e., immersed in) an electroporation solution; positioning a pair of electrodes in said electroporation solution; positioning a micropipette between the pair of

electrodes, with the micropipette having an outlet opening that is in fluid contact with the electroporation solution; introducing the compound through the outlet opening and into the electroporation solution; and  
5       subjecting the cells to a current pulse across the pair of electrodes, the current pulse sufficient to cause the compound to pass through the cell membranes of the cells and into the cells by electroporation.

10       A third aspect of the present invention is a method for visually detecting the location of binding events within a cell. The method comprises introducing a fusion protein into the cell, the fusion protein comprising a binding domain and a detectable domain; and  
15       then visually detecting the location of increased levels of the detectable domain within the cell, the location of increased levels of the detectable domain indicating the location of a compound within the cell to which the binding domain specifically binds.

#### Brief Description of the Drawings

In the drawings which form a portion of the original disclosure of the invention:

5       FIGS. 1a and 1b are perspective and schematic views of the electroporation apparatus of the invention.

FIGS. 2a-2b are views of interlinked electrodes of the invention.

10       FIG. 3 is a graph illustrating the relative fluorescence intensity of green fluorescent protein (GFP) as a function of time.

FIG. 4 is a histogram illustrating the relative fluorescence intensity distribution of GFP in RBL cells transfected with cycle 3 GFP mRNA.

15       FIG. 5 is a graph illustrating the diffusion-mediated decrease in peak local fluorescence intensity for cells transfected with wildtype (wt) GFP and cycle 3 GFP mRNA, as a function of time.

FIG. 6 is a graph illustrating the relationship between the square of the peak radius of GFP as a function of time. This relationship is used in obtaining the diffusion coefficient of GFP.

5           FIG. 7 is a bar diagram illustrating the diffusion coefficients of cycle 3-GFP and wt GFP.

FIG. 8 is a normalized intensity profile of GFP-K-ras transfected RBL cells at selected times after a plasma membrane-localized UV pulse.

10           FIG. 9 is a graph illustrating the time course of decrease in local fluorescence of GFP-K-ras localized to the plasma membrane.

#### Detailed Description of the Invention

As noted above, the present invention provides  
15       a method for transfecting cells with an exogenous compound. The method comprises:

(i) providing a cell support, with said cell support having a top surface portion with cells adhered thereto, and with said cells  
20       being in contact with an electroporation solution;

(ii) positioning a pair of electrodes in said electroporation solution;

(iii) positioning a micropipette between  
25       said pair of electrodes, with said micropipette having an outlet opening in fluid contact with said electroporation solution;

(iv) introducing said compound through  
30       said outlet opening and into said electroporation solution; and

(v) subjecting said cells to a current pulse across said pair of electrodes, said current pulse sufficient to cause said compound to pass through the cell membranes of said  
35       cells and into said cells by electroporation.

Any suitable compound may be introduced into a cell by the instant invention, including RNA, DNA, proteins, peptides, and small organic molecules. The present invention is particularly advantageous for introducing  
5 oligonucleotides, such as antisense oligonucleotides, or other compounds that are cell membrane impermeant. The method may be used to introduce a fusion protein comprised of a binding domain and a detectable domain, as discussed in detail below.

10 Electroporation solutions, electrode materials, and the electrical parameters for carrying out electroporation are either known to those skilled in the art or will be readily apparent in light of the disclosure set forth herein.

15 Micropipettes useful for carrying out the invention include any syringe or injection device that discharges a small sample volume (typically as a liquid suspension of the compound of interest) through an outlet opening, with capacities for discharging 100, 50, 25, 10,  
20 5, 2 or 1 microliters or less (and not more than the indicated capacity) being illustrative. Smaller sample volumes are generally preferred.

The methods described herein are particularly  
25 advantageously employed in carrying out a method for visually detecting the location of binding events within a cell. Such a method comprises:

(a) introducing a fusion protein into said cell, said fusion protein comprising a binding domain and a detectable domain (e.g., a  
30 fluorescent protein); and then

(b) visually detecting the location of increased levels of said detectable domain within said cell, the location of increased levels of said detectable domain indicating the  
35 location of a compound within said cell to which said binding domain specifically binds.

While the introducing step may be carried out by introducing RNA encoding the fusion protein into said cell, wherein said fusion protein is translated from said RNA, the introducing step may also be carried out by  
5 introducing the fusion protein directly into the cell. Further, while the fusion protein (or RNA encoding the same) may be introduced by the methods and apparatus described herein, the fusion protein (or RNA encoding the same) may also be by other suitable techniques, such as  
10 microparticle bombardment.

Suitable detectable domains include fluorescent proteins, such as green fluorescent protein (GFP), apoaeguorin, and analogs and derivatives thereof. Green fluorescent protein is derived from the jellyfish  
15 *Aequorea victoria* and has been expressed in a wide variety of microbial, plant, insect and mammalian cells. A. Crameri et al., *Nature Biotech.* 14, 315-319 (1996). Any detectable domain may be employed, and other suitable detectable domains include other fluorophores or  
20 fluorescent indicators, such as a fusion tag with any binding domain such as avidin, streptavidin and ligand binding domains of receptors. coupling of biotin or other ligands to the fluorophore or indicator of interest using a dextran matrix or other linker system. Visually  
25 detectable detectable domains are preferred (e.g., those that can generate a signal that can be displayed on a visual monitor, on film or photographs, through a microscope, etc.).

Methods employing the introduction of fusion  
30 proteins into a cell, as described above, are useful in a variety of different techniques. For example, the method can be an assay for tyrosine phosphorylation, and said binding domain a tyrosine kinase Syk or a fragment thereof that binds to the FcεRI receptor. The method can  
35 be an assay for diacylglycerol and the binding domain the C1 fragment of protein kinase C or a fragment of said C1 fragment that binds to diacylglycerol. The method can be



an assay for nuclear translocation or transcriptional activation, and said binding domain CaM-Kinase IV. The method can be an assay for cell secretion, and the binding domain catalase. The foregoing are illustrative, and many other applications of the instant invention will be readily apparent to those skilled in the art.

The electroporation apparatus 10 will now be described in detail and is illustrated in FIGS. 1a and 1b. The electroporation apparatus 10 is designed to introduce exogenous material into cells. Specifically, the apparatus includes a base member 15 configured for holding a cell support. The cell support has a top surface portion which is generally flat for carrying adherent cells. A cover glass for the support may be used with a 25 mm circle micro cover slide of Model No. 19063 sold by VWR Scientific of Media, Pennsylvania being preferred. The surface portion may be made from glass or plastic. A ring made of delrin® or another appropriate polymer may be present on the cell support to carry a buffer solution. An electrode carrier 25 is operably associated with the base member 15 and has a bottom surface portion which is generally flat. The electrode carrier is most preferably made of DECRIN® polymer but may be constructed of any appropriate material, preferably a polymeric material. The electrode carrier 25 is connected to first 30 and second 35 electrodes creating an electric field which impacts the cells. The structures of the two electrodes are various and include, for example, wires and sheets. Sheet electrodes are preferred since they have been found to minimize inconsistencies which may exist in the electric field. The electrodes 30 and 35 are preferably spaced between about 3 mm to 5 mm apart, and are more preferably about 4 mm apart. The electrodes can be formed from a number of appropriate materials, and are preferably formed from platinum. The electrodes are designed to preferably accommodate a peak voltage of 200 to 400 V with an RC

discharge time constant in the 10 to 500 ms range. Slightly different field strengths may be required depending on the type of cells used. It is especially preferred that the electrodes be positioned with the carrier to be generally parallel to one another.

5 In accordance with the invention, a channel 40 is formed within the electrode carrier 25 and is positioned between the first and second electrodes 30 and 35 as illustrated in FIG. 1b. The channel 40 allows for exogenous material to be introduced through the channel and into contact with the cells. Specifically, stainless steel tubing 45 is inserted into the channel 40 and serves as a guide. Commercially preferred tubing is Model No. A-HTX-B sold by the Lee Company of Essex, Connecticut and has an inner diameter of 0.071 inch and an outer diameter of 0.095 inch. A threaded steel sleeve 50 extends around the outer diameter of the top of flexible tubing 55 with Model No. TMCA 32020302 being preferred. The flexible tubing 55 is present within the stainless steel tubing which facilitates the transport of the exogenous material to the cells. In particular, the flexible tubing serves as a micropipette. Teflon® tubing of Model No. TUTA 1226930L sold by Small Parts, Inc. of Miami Lakes, Florida is especially preferred, having an inner diameter of 0.012 inch and an outer diameter of 0.065 inch. A wire 60 is used as a plunger within the Teflon® tube to inject the exogenous material with Model No. A-SWGX-120 sold by The Lee Company. The wire 60 is used to insert a variety of materials such as, for example, proteins, dextrans, and other agents. Various volume sample sizes such as those less than 100  $\mu$ l, less than 50  $\mu$ l, less than 25  $\mu$ l, less than 10  $\mu$ l, 5  $\mu$ l or less, between 1 and 2  $\mu$ l, and more typically less than 1  $\mu$ l may be injected by the wire.

35 The electrode carrier 25 is connected to a bracket, which bracket is connected by a pair of linear bearings which are in turn connected to a double rail

track. The double rail track and bearings are sold commercially by TECHNO Linear Bearing of New Hyde Park, New York. The preferred bearing has catalog number HL 4500M222001 and the preferred double rail has a catalog number HL 4222M0010300.

5 Cushioning means 70 such as a foam pad for example, is positioned between the base member 15 and the cell support for facilitating the generally parallel orientation of the cell support top surface portion and  
10 the electrode carrier bottom surface portion. Various appropriate cushioning means may be used for the purposes of the invention.

In one embodiment, the first and second electrodes may be members of an interlinked set of  
15 electrodes 100 as illustrated in FIGS. 2a-2d. As illustrated, the members are configured in various grid porator designs with the distance between grid lines being of various values, namely 60  $\mu\text{m}$ , 120  $\mu\text{m}$ , 200  $\mu\text{m}$ , along with the combination of 120  $\mu\text{m}$  and 340  $\mu\text{m}$ . The  
20 grid porator may be formed on the bottom of the electrode carrier.

The electroporation apparatus may also include a power supply 115 and a controller 120 operably associated with the power supply and the first and second  
25 electrodes. The power supply 115 charges a capacitor that provides a voltage and corresponding current between the electrodes. A preferred power supply is sold by BIO-RAD as Model 1000/500. A capacitor and relay system may also be employed providing, for example, 200-400 volts  
30 per cm. The capacitor and relay system is controlled by a personal computer equipped with a relay board.

It is useful to measure the current during transfection of cells with the exogenous compound. For example, a detection of an increase in current may  
35 indicate that the leveling is not flat or that the ionic strength of a buffer solution is not correct. A decrease in current may indicate that air bubbles exist in the

fluid transporting the exogenous material or that the first and second electrodes are corroded.

5 In an alternative embodiment, the electroporation apparatus may further comprise a well member 130 having an opening formed therein. The opening is defined by walls configured for receiving the electrode carrier. The well member has a bottom surface configured for contacting to the cell support top surface portion, so that the walls enclose the electroporation chamber.

10 Preferably, the electroporation apparatus further includes positioning means 140 for maintaining the electrode carrier bottom surface in a spaced relationship to the cell support top surface. As a result, an electroporation chamber is defined therebetween. The channel formed in the electrode carrier is in fluid communication with the electroporation chamber. Preferably, the positioning means is configured for maintaining the electrode carrier bottom surface portion and the cell support top surface portion not more than 100  $\mu\text{m}$  apart. The positioning means may include, for example, a lip peripheral edge portion which is positioned below the electrode carrier which is preferably spaced 100  $\mu\text{m}$  from the bottom of the electrode carrier. The lip has formed therein two opposing elliptical openings which allow for the insertion of the first and second electrodes. In the center of the lip, an opening is formed which is sized to accommodate the stainless steel tubing. The lip is made from appropriate electrically non-conductive polymeric material. Other appropriate positioning means include any suitable structure on the electrode carrier or base member which allows for the proper spacing.

30 The present invention is illustrated in greater detail in the following non-limiting Examples. In the following Examples, mM means millimoles; nM means nanomoles,  $\mu\text{M}$  means micromoles;  $^{\circ}\text{C}$  means degrees

Centigrade;  $\mu\text{L}$  means microliters;  $\mu\text{g}$  means micrograms; ATP means adenosine triphosphate;  $\text{cm}^2$  means centimeters squared;  $\mu\text{m}^2$  means micrometers squared; s means seconds; ms means milliseconds; nm means nanometers; mm means millimeters; W means watts; mW means milliwatts; UV means ultraviolet.

Example 1  
Generation of Transcription Vectors for Wildtype GFP,  
Cycle 3 Mutant GFP, and K-ras 4B GFP

10           Vector pXen2 containing the 3' untranslated region (UTR) of *Xenopus laevis*  $\beta$ -globin gene was provided by Dr. Kevin Peters (Duke University). Plasmids for wildtype GFP (pRAY1) and Cycle 3 mutant of GFP plasmid (pBAD-GFP) were obtained from Dr. Donald Lo (Duke University) and Affymax (Palo Alto, CA), respectively.

15           cDNA encoding human K-ras 4B was provided by Dr. Patrick Casey (Duke University).

          The 3' untranslated region of the *Xenopus laevis*  $\beta$ -globin gene was cloned into the in vitro translation vector pSPUTK (Stratagene, La Jolla, CA) using the restriction sites *EcoRI* and *BamHI*. An *ApaI* site was introduced into the wildtype GFP by PCR with the primer 5'-CAACGGGCCCCAATGAGTAAAGGAGAAGAAC-3' (SEQ ID NO:1) (containing the *ApaI* site) as the sense primer, and the SP6 primer 5'-GCATTTAGGTGACACTATAG-3' (SEQ ID NO:2) as the antisense primer. The plasmid pRAY1 was used as a template. The PCR fragment was cloned into the *ApaI* and *XbaI* sites of the modified pSPUTK vector, resulting in the transcription vector pHIOWt. This vector contains the wildtype GFP followed by the 3' UTR of  $\beta$ -globin.

20           Additional restrictions sites (*ApaI* and *XbaI*) were introduced into the cycle 3 GFP mutant by PCR (sense primer 5'-CAACGGGCCCCATATGGCTAGCAAAGGAG-3' (SEQ ID NO:3); antisense primer: 5'-CAACTCTAGATTATTTGTAGAGCTCATCC-3' (SEQ ID NO:4)). The plasmid pBAD-GFP was used as a template.

25           In the same cloning step, the *EcoRI* site located in the

3' end of the gene was deleted by mutagenesis. Replacement of the wildtype GFP in the vector PHIR0wt with the cycle 3 GFP resulted in the in vitro transcription vector pHIR01.

5 K-ras 4B was cloned into vector pHIR01 (K-ras 4B/pHIR01) by adding additional BamHI sites to both ends of the gene by PCR (sense primer: 5' CAACGGATCCATGACTGAATATAAACTTGTG-3' (SEQ ID NO:5);  
10 antisense primer: 5' -GTTGGGATCCTTACATAATTACACACTTTGTC-3' (SEQ ID NO:6)).

### Example 2 In vitro Transcription and RNA Processing

Plasmids were linearized downstream from the 3' UTR with either SacI (PHIR0wt), EcoRI (pHIR01) or ClaI (K-ras 4B/pHIR01). In vitro transcription with SP6 RNA polymerase was performed according to the manufacturer's protocol using a commercial kit (mMESSAGE mMACHINE®, Ambion, Austin, TX). 10 mM EDTA was used to terminate the reaction. The RNA was purified by column chromatography (RNeasy® column, Qiagen, Chatsworth, CA) followed by the addition of the poly-A tail. Polyadenylation was carried out for 30 minutes at 37°C<sup>25</sup> in a 50 µl reaction mixture containing 40 mM Tris-HCl (pH 8.0), 10 mM MgCl<sub>2</sub>, 2.5 mM MnCl<sub>2</sub>, 250 mM NaCl, 0.25 µg/µL RNA, 250 µM ATP, and 5  
25 units poly(A) polymerase (Life Technologies, Gaithersburg, MD). The reaction was terminated by the addition of 20 mM EDTA. Unincorporated ATP and salt were removed by applying the mRNA to a RNeasy column. The eluent was dried and mRNA was dissolved at 2 µg/µl in  
30 electroporation buffer (5 mM KCl, 125 mM NaCl, 20 mM HEPES pH 7.4 and 10 mM glucose).

### Example 3 Cell Culturing and Electroporation

RBL 2H3 cells were maintained in Dulbecco's  
35 Minimum Essential Medium (DMEM) supplemented with 20%

fetal bovine serum (Life Technologies, Gaithersburg, MD) at 37°C with 5% CO<sub>2</sub>. The cells were plated at 5 X 10<sup>4</sup> cells/cm<sup>2</sup> on glass cover slips, and were allowed to attach to the coverslip for at least 3 hours. A small-volume electroporation device for adherent cells was used for electroporation. After replacement of the medium in the dish with electroporation buffer, the mRNA sample was applied (1 µl at 1 - 2 µg/µl). Electroporation was performed at 350 V/cm, using 3 voltage pulses, each 40 ms long and 40 s apart. After transfection, the electroporation buffer was replaced with DMEM (without phenol red). Until observation, cells were kept at 37°C for cycle 3 GFP and at 30°C for wildtype GFP. The lower temperature was necessary to observe sufficient wildtype GFP fluorescence.

#### Example 4 Marking of GFP by UV-laser Pulses

GFP-transfected cells were monitored using an Odyssey confocal imaging system (Noran Inc., Middleton, WI) mounted on an inverted Nikon Diaphot microscope. In combination with a Raptor Imaging board (Bitlow, Woburn, MA) and Eye Image Calculator software (IO Industries, London, Ontario, Canada), this system captures images every 16.7 ms. GFP fluorescence was excited at 488 nm and was monitored above 495 nm. GFP was locally marked by using a focused UV-laser (365 nm; Enterprise, Coherent Inc., Palo Alto, CA). The UV-laser was coupled into the optical axis through the fluorescence microscope port using a UV-reflecting dichroic mirror. UV-laser intensities at the sample were estimated to be 1 mW. A computer controlled shutter with an opening time of typically 5 ms was used to locally enhance the fluorescence of GFP.

### Example 5

#### Diffusion Analysis

5 The diffusion analysis was based on the observation that the initial increase in peak fluorescence induced by a laser pulse can be fit by a 2-dimensional Gaussian distribution as follows:

$$F_0(x, y) = C * \exp(-((x - x_0)^2 + (y - y_0)^2) / a_0^2)$$

10 with x and y as the pixel values and  $F_0$  as the local fluorescence intensity. Sequential images recorded after the UV-pulse were normalized to an averaged image that was recorded before the pulse. The decreased amplitude and the increased radius ( $a_n$ ) of the fluorescence peak in each image was fit by 2-dimensional Gaussian functions as follows:

$$15 \quad F_n(x, y) = C * (a_0^2 / a_n^2) * \exp(-((x - x_0)^2 + (y - y_0)^2) / a_n^2)$$

(assuming mass conservation). A least-squares fit routine was used to determine the radius of each Gaussian peak,  $a_n$ . The diffusion coefficient was then determined from a graph of the square of the radius,  $a_n^2$  versus time (FIG. 6). The diffusion coefficient

20 is directly obtained from the slope of this graph:

$$\Delta y / \Delta x = 4 * D$$

(with D as the diffusion coefficient).

### Example 6

#### mRNA Transfection of Adherent Mammalian Cells

25 A mRNA transfection technique for mammalian cells was developed as an alternative to conventional plasmid or viral transfection methods. The strategy underlying this technique involving transcribing RNA in

30 vitro and electroporating the processed mRNA into



adherent cells using a small volume electroporation device that uses 1  $\mu$ L or less of sample volume. The vector used for the *in vitro* transcription consisted of a 5' untranslated region from *Xenopus laevis*  $\beta$ -globin (see D. Falcone, and D.W. Andrews, *Mol. and Cell. Biol.* 11, 2565-2664 (1991); M.R. Green et al., *Cell* 32, 681-94 (1983)), a Kozak sequence (M. Kozak, *Nucl. Acid Res.* 15, 8125-8148 (1987)), and a GFP insert and a 3' UTR from *Xenopus laevis*  $\beta$ -globin (R.L. Tanguay and D.R. Gallie, *Mol. Cell. Biol.* 16, 146-156 (1996)). *In vitro* transcription was performed in the presence of a  $^3$ G(5')ppp(5')G cap analog. High level translation was observed only when a poly(A) tail was added to the RNA *in vitro* using poly(A) polymerase.

15

#### Example 7 Translation Efficiency

The translation efficiency of the mRNA construct of Example 6 was tested by measuring the GFP fluorescence intensity of rat basophilic leukemia (RBL) cells electroporated with the *in vitro* synthesized mRNA. Transfection of a 3 x 3 mm region on the coverslip with up to  $2 \times 10^4$  cells required 1  $\mu$ L of mRNA at a concentration of 1  $\mu$ g/ $\mu$ L.

The variability in electroporation of mRNA was quantitatively investigated by measuring the relative fluorescence intensity of GFP in 165 cells and by representing the intensity distribution in a histogram (FIG. 4, measured 10 hours after transfection). The appearance of GFP fluorescence is nearly linear with time (FIG. 3), except for a 1 hour lag time immediately after transfection. This lag time is slightly shorter than the 90 minutes required for functional GFP formation, as reported in earlier studies. Cf., A. Crameri et al., *supra*. GFP fluorescence reached a plateau after 10 hours and remained nearly constant for at least 48 hours. The termination of further fluorescence increase after 10

hours could be explained by the degradation of mRNA and the plateau phase suggests that the expressed GFP is stable for at least 48 hours.

Example 8  
Fluorescence Enhancement by Spatially Localized  
UV-laser Pulses

5

GFP has a main absorbance peak at 395 nm and a smaller peak at 475 nm. M. Chalfie et al., *Science* 263, 802-805 (1994). In vitro studies have previously shown that UV irradiation of GFP at 280 nm leads to a decrease of the 395 nm peak and an increase of the 475 nm peak. A.B. Cubitt et al., *TIBS* 20, 448-455 (1995). This increase in fluorescence appears to be sustained in vitro. The precise mechanism of the fluorescent enhancement is not yet understood.

10

15

The unique photo-isomerization character of GFP was examined to determine whether it could be used to study the spatial dynamics of GFP-tagged proteins in single cells. A UV-laser (365 nm) was coupled into the confocal microscope (488 nm, blue laser line), while the focused UV-laser was used to locally enhance the blue excited fluorescence of GFP within a cell. Depending on the UV-pulse energy, up to a 3-fold increase in local fluorescence was observed. The spatial spreading of the fluorescence after the UV-pulse was analyzed by sequential imaging using a confocal microscope.

20

25

Example 9  
Diffusion Analysis of Wildtype GFP and Cycle 3 GFP

Cycle 3 GFP was originally generated by mutating GFP with a DNA shuffling technique and selecting bacteria with maximal fluorescence intensity. See Cramer et al., *supra*. In this initial study, it was reported that the high fluorescence of expressed cycle 3 GFP is in part the result of a reduction of the amount of wildtype GFP in inclusion bodies. This report suggested

30

35

that wildtype GFP may have a hydrophobic surface that causes self-aggregation and is therefore not suitable as a fluorescent tag for protein localization studies.

5 This hypothesis was tested by using the local UV-marking technique and directly comparing the mobility of cycle 3 GFP with that of wildtype GFP. FIG. 5 shows measurements of the decrease in peak fluorescence intensity at the UV-laser spot as a function of time. Wildtype GFP is much less mobile than the cycle 3 mutant  
10 GFP, suggesting that cycle 3 GFP has less binding interactions in mammalian cells than wildtype GFP.

The actual diffusion coefficient of cycle 3 GFP was measured to determine whether its value is consistent with it being a freely diffusing molecule. For this  
15 purpose, a 2-dimensional Gaussian distribution was fit to the fluorescence peak in a series of images obtained after the UV-pulse, under the assumption that an ideal diffusion process retains its Gaussian profile over time. A simultaneous decrease in and widening of the peak  
20 intensity after the UV-laser pulse was observed. All images were normalized to an averaged fluorescence image recorded immediately before the UV-pulse. The diffusion coefficient of GFP was obtained by graphing the square of the peak radius as a function of time (FIG. 6). Using  
25 this analysis, cycle 3 GFP was found to diffuse 10 times faster than wildtype GFP (FIG. 7). The diffusion coefficient of cycle 3 GFP was  $43 \mu\text{m}^2/\text{s}$  with a standard error of  $11 \mu\text{m}^2/\text{s}$  (compared to  $4.2 \mu\text{m}^2/\text{s} + 1.2 \mu\text{m}^2/\text{s}$  for wildtype GFP). Thus, cycle 3 GFP appears to be nearly  
30 freely diffusible, and is therefore ideally suited as a fusion tag for protein localization studies.

#### Example 10

##### Expression of cycle 3 GFP-K-ras protein (GFP-K-ras)

Immunolocalization and fractionation studies  
35 have shown that K-ras (M.S. Boguski, M. S. and F. McCormick, Nature 366, 643-654 (1993)), a small

GTP-binding protein, is localized to the plasma membrane by a C-terminal farnesyl group and a nearby polybasic region. P.J. Casey, *Science* 268, 221-225 (1995).

5 mRNA encoding GFP-K-ras fusion protein was micro-electroporated into RBL-cells to test the extent of localization of K-ras in intact cells. Fluorescence images showed that K-ras was enriched at the plasma membrane of RBL-cells. While confocal images showed a markedly higher concentration of expressed GFP K-ras fusion protein at the plasma membrane, a lower  
10 concentration of GFP could also be observed throughout the cytosol but not inside the nucleus. Such a distribution could be the result of an equilibrium between K-ras bound to the plasma membrane and K-ras  
15 diffusible in the cytosol.

#### Example 11

##### Measurement of the plasma membrane dissociation rate of K-ras

UV-laser mediated fluorescence enhancement of plasma membrane localized K-ras was used to test the  
20 equilibrium hypothesis of Example 10. Following a UV-pulse, the marked GFP-K-ras rapidly moved away from the focus region as indicated by a decrease in local fluorescence intensity. This decrease in fluorescence was not the result of a lateral diffusion of GFP-K-ras within  
25 the plasma membrane, since only a decrease in fluorescence and no widening of the Gaussian-profile could be observed (FIG. 8). Thus, the rapid reduction in local fluorescence must result from K-ras dissociating from the membrane and diffusing away from the plasma  
30 membrane as a cytosolic protein. We determined the rate of dissociation of K-ras from the plasma membrane by graphing the decrease in local fluorescence as a function of time (FIG. 9). Re-equilibration between plasma membrane K-ras and cytosolic K-ras occurred on a time  
35 scale of a few seconds.

The decrease in fluorescence could be best fit by two time constants of  $90 \text{ ms} \pm 40 \text{ ms}$  and  $1.5 \text{ s} \pm 0.7 \text{ s}$ , respectively (FIG. 9,  $N = 5$ ). The fast time constant of 90 ms was measured for a small subfraction of the marked GFP and can be explained by the rapid diffusion of cytosolic GFP-K-ras that was close to the plasma membrane and that was also illuminated by the UV-pulse. The 1.5 s time constant would then be the relevant value that describes the dissociation of K-ras from the plasma membrane. Because most plasma membrane K-ras dissociates away from the plasma membrane every 1.5 s, the observed high concentration of K-ras at the plasma membrane and the low concentration in the cytosol can only be sustained if cytosolic K-ras also binds rapidly back to the plasma membrane. Thus, K-ras appears to exist in a dynamic equilibrium and rapidly switches between a plasma membrane bound form and a cytosolic form with a plasma membrane dissociation rate of 1.5 s.

#### Example 12

##### Measurement of Cell-Wide Fluorescence Redistribution After Local Fluorescence Enhancement or Photobleaching

The dynamic equilibrium hypothesis was further investigated by analyzing the fluorescence redistribution across the cell after continued local fluorescence enhancement and continued local photobleaching. An experiment was conducted in which the fluorescence of GFP-K-ras was locally enhanced at the marked location using a series of 20 UV-pulses applied over 2 minutes. Within one minute after local enhancing GFP-K-ras and producing a continued local "source" of enhanced GFP fluorescence, GFP-K-ras was again evenly distributed across the plasma membrane and cytosol as indicated by a cell-wide increase in fluorescence intensity. The laser line of the UV-laser was then switched to its visible lines (mostly 488 nm and 514 nm) for local photobleaching measurements and the same protocol was repeated. Again,

within a minute after generating a persistent local "sink" for GFP at the same place, the fluorescence intensity was evenly reduced across the entire plasma membrane and cytosol. It should be noted that no measurable reduction in GFP-K-ras fluorescence intensity could be observed for at least 30 minutes after enhancement, suggesting that the UV-laser mediated fluorescence enhancement is an irreversible or slowly reversible process in intact cells. The results from this local source-and-sink protocol are consistent with a dynamic equilibrium model in which GFP-K-ras rapidly redistributes between a plasma membrane bound and a cytosolic form.

The foregoing Examples are illustrative of the present invention, and are not to be construed as limiting thereof. The invention is defined by the following claims, with equivalents of the claims to be included therein.

## SEQUENCE LISTING

## (1) GENERAL INFORMATION:

- (i) APPLICANT: Meyer, Tobias
- (ii) TITLE OF INVENTION: Method of Transfecting Cells By Electroporation and Apparatus For Same
- (iii) NUMBER OF SEQUENCES: 6
- (iv) CORRESPONDENCE ADDRESS:
  - (A) ADDRESSEE: Kenneth D. Sibley
  - (B) STREET: Post Office Drawer 34009
  - (C) CITY: Charlotte
  - (D) STATE: North Carolina
  - (E) COUNTRY: USA
  - (F) ZIP: 28234
- (v) COMPUTER READABLE FORM:
  - (A) MEDIUM TYPE: Floppy disk
  - (B) COMPUTER: IBM PC compatible
  - (C) OPERATING SYSTEM: PC-DOS/MS-DOS
  - (D) SOFTWARE: PatentIn Release #1.0, Version #1.30
- (vi) CURRENT APPLICATION DATA:
  - (A) APPLICATION NUMBER:
  - (B) FILING DATE:
  - (C) CLASSIFICATION:
- (vii) ATTORNEY/AGENT INFORMATION:
  - (A) NAME: Sibley, Kenneth D.
  - (B) REGISTRATION NUMBER: 31,665
  - (C) REFERENCE/DOCKET NUMBER: 5405-132
- (ix) TELECOMMUNICATION INFORMATION:
  - (A) TELEPHONE: (919) 420-2200
  - (B) TELEFAX: (919) 881-3175
  - (C) TELEX: 575102

## (2) INFORMATION FOR SEQ ID NO:1:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 31 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

CAACGGGCCC AAATGAGTAA AGGAGAAGAA C

31

(2) INFORMATION FOR SEQ ID NO:2:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 20 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

GCATTAGGT GACACTATAG

20

(2) INFORMATION FOR SEQ ID NO:3:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 28 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:

CAACGGGCCC ATATGGCTAG CAAAGGAG

28

(2) INFORMATION FOR SEQ ID NO:4:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 29 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:

CAACTCTAGA TTATTTGTAG AGCTCATCC

29

(2) INFORMATION FOR SEQ ID NO:5:

- (i) SEQUENCE CHARACTERISTICS:



- 23 -

- (A) LENGTH: 31 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:

CAACGGATCC ATGACTGAAT ATAACTTGT G

31

(2) INFORMATION FOR SEQ ID NO:6:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 32 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:

GTTGGGATCC TTACATAATT ACACACTTTG TC

32

## That Which Is Claimed:

1. An electroporation apparatus for introducing exogenous material into cells, said apparatus comprising:
  - 5 a base member configured for holding a cell support, the cell support having a top surface portion, said top surface portion configured for carrying adherent cells;
  - an electrode carrier operably associated with said base member, said electrode carrier having a bottom surface portion;
  - 10 a first electrode connected to said electrode carrier;
  - a second electrode connected to said electrode carrier;
  - 15 said electrode carrier having a channel formed therein, with said channel positioned between said first electrode and said second electrode, so that said exogenous material may be introduced through said channel and into contact with said cells.
  - 20
2. An electroporation apparatus according to claim 1, further comprising:
  - positioning means for maintaining said electrode carrier bottom surface in a spaced relationship to said cell support top surface to define an electroportation chamber therebetween, with said channel formed in said electrode carrier being in fluid communication with said electroporation chamber.
  - 25
3. An electroporation apparatus according to claim 2, wherein said positioning means is configured for maintaining said electrode carrier bottom surface portion and said cell support top surface portion not more than 500  $\mu\text{m}$  apart.
- 30

4. An electroporation apparatus according to claim 2, further comprising a well member having an opening formed therein, with said opening defined by walls configured for receiving said electrode carrier, and with said well member having a bottom surface configured for contacting to said cell support top surface portion, so that said walls enclose said electroporation chamber.

5. An electroporation apparatus according to claim 2, further comprising cushioning means positioned between said base member and said cell support for facilitating the generally parallel orientation of said cell support top surface portion and said electrode carrier bottom surface portion.

6. An electroporation apparatus according to claim 1, wherein said first electrode and said second electrode are generally parallel to one another.

7. An electroporation apparatus according to claim 1, wherein said cell support top surface portion and said electrode carrier bottom surface portion are generally flat.

8. An electroporation apparatus according to claim 1, wherein said first electrode and said second electrode are each members of an interlinked set of electrodes.

9. An electroporation apparatus according to claim 1, further comprising:  
a power supply; and  
a controller operably associated with said power supply and said first and second electrodes.

10. A method for transfecting cells with an exogenous compound, comprising:

5 providing a cell support, with said cell support having a top surface portion with cells adhered thereto, and with said cells being in contact with an electroporation solution;

positioning a pair of electrodes in said electroporation solution;

10 positioning a micropipette between said pair of electrodes, with said micropipette having an outlet opening in fluid contact with said electroporation solution;

introducing said compound through said outlet opening and into said electroporation solution; and

15 subjecting said cells to a current pulse across said pair of electrodes, said current pulse sufficient to cause said compound to pass through the cell membranes of said cells and into said cells by electroporation.

20 11. A method according to claim 10, wherein said compound is RNA.

12. A method according to claim 11, wherein said RNA encodes a fusion protein, said fusion protein comprising a binding domain and a detectable domain.

25 13. A method according to claim 12, wherein said detectable domain comprises a fluorescent protein.

14. A method according to claim 10, wherein said compound is a peptide or protein.

30 15. A method according to claim 10, wherein said compound is a fusion protein, said fusion protein comprising a binding domain and a detectable domain.

16. A method according to claim 15, wherein said detectable domain comprises a fluorescent protein.

17. A method according to claim 10, wherein said compound is an oligonucleotide.

5 18. A method according to claim 10, wherein said compound is an antisense oligonucleotide.

19. A method for visually detecting the location of binding events within a cell, comprising:  
introducing a fusion protein into said cell,  
10 said fusion protein comprising a binding domain and a detectable domain; and then  
visually detecting the location of increased levels of said detectable domain within said cell, the location of increased levels of said detectable domain  
15 indicating the location of a compound within said cell to which said binding domain specifically binds.

20. A method according to claim 19, wherein said introducing step is carried out by introducing RNA encoding said fusion protein into said cell, wherein said  
20 fusion protein is translated from said RNA.

21. A method according to claim 19, wherein said detectable domain comprises a fluorescent protein.

22. A method according to claim 19, wherein said introducing step is carried out by electroporation.

25 23. A method according to claim 19, wherein said introducing step is carried out by microparticle bombardment

24. A method according to claim 19, wherein said method is an assay for tyrosine phosphorylation and

said binding domain is tyrosine kinase Syk or a fragment thereof that binds to the FcεRI receptor.

5           25. A method according to claim 19, wherein said method is an assay for diacylglycerol and said binding domain is the C1 fragment of protein kinase C or a fragment of said C1 fragment that binds to diacylglycerol.

10           26. A method according to claim 19, wherein said method is an assay for nuclear translocation or transcriptional activation, and said binding domain is CaM-Kinase IV.

          27. A method according to claim 19, wherein said method is an assay for cell secretion and said binding domain is catalase.




FIG. 1A




FIG. 1B



FIG. 2A




FIG. 2B




FIG. 2C





FIG. 2D






FIG. 3

5/10




FIG. 4

6/10




FIG. 5

7/10




FIG. 6

8/10




FIG. 7

9/10




FIG. 8

10/10




FIG. 9



# INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US97/16721

## A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) : C12N 13/00, 15/09

US CL : 435/173.5, 173.6; 935/52, 76

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 435/173.5, 173.6; 935/52, 76

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

APS:

terms: fusion protein, chimera, fluoresc, syk, catalase, cam kinase

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	US 5,349,053 A (N.F. LANDOLFI) 20 September 1994, especially abstract and column 9, lines 45-55.	19-27
Y	US 5,420,264 A (SEED et al.) 30 May 1995, especially abstract and column 30, lines 36-48).	19-27
Y	US 5,512,457 A (LYMAN et al.) 30 April 1996, especially abstract and column 16, lines 33-47.	19-27
Y	US 5,550,054 A (WITTE et al. ) 27 August 1996, especially the abstract.	19-27
A	US 4,882,281 A (HILLIARD et al.) 21 November 1989.	1-18

☒ Further documents are listed in the continuation of Box C. ☐ See patent family annex.

* Special categories of cited documents:	*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
*A* document defining the general state of the art which is not considered to be of particular relevance	*X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
*G* earlier document published on or after the international filing date	*Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
*L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*A* document member of the same patent family
*O* document referring to an oral disclosure, use, exhibition or other means	
*P* document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search

01 DECEMBER 1997

Date of mailing of the international search report

09 JAN 1998

Name and mailing address of the ISA/US  
Commissioner of Patents and Trademarks  
Box PCT  
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

JON P. WEBER, PH. D.

Telephone No. (703) 308-0196

## INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US97/16721

## C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	US 5,128,257 A (B.W. BAER) 07 July 1992.	1-18
A	US 5,422,272 A (PAPP et al.) 06 June 1995.	1-18
A	JP 08,322,548 (NIKON) 10 December 1996.	1-18
A	MCCORMICK et al. A Low Cost Microprocessor-Controlled Electrofusion and Electroporation System. J. Chem. Tech. Biotechnol. 1992, Vol. 554, No. 2, pages 159-169.	1-18

# INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US97/16721

## Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:
  
2. ☐ Claims Nos.:  
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
  
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

Please See Extra Sheet.

1. ☒ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
  
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.  
☐ No protest accompanied the payment of additional search fees.

# INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US97/16721

## BOX II. OBSERVATIONS WHERE UNITY OF INVENTION WAS LACKING

This ISA found multiple inventions as follows:

This application contains the following inventions or groups of inventions which are not so linked as to form a single inventive concept under PCT Rule 13.1. In order for all inventions to be searched, the appropriate additional search fees must be paid.

Group I, claims 1-18, drawn to an electroporation apparatus and a first method of transfecting cells with the same electroporation apparatus.

Group II, claims 19-27, drawn to a method of visually locating binding in cells by introducing RNA encoding protein into cells.

The inventions listed as Groups I and II do not relate to a single inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons: The first process corresponds to using a particular electroporation apparatus to transfect cells with a desired RNA encoding a protein, while the second process does not require the electroporation apparatus and may use any method of transfection known in the art such as calcium phosphate, ultrasonication, microparticle bombardment (specifically claimed), for example. Hence the apparatus does not link these two methods.

Therefore, the claims are not so linked by a special technical feature within the meaning of PCT Rule 13.2 so as to form a single inventive concept.

**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

**BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☐ **FADED TEXT OR DRAWING**
- ☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☐ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**